To include your compound in the COVID-19 Resource Center, submit it here.

Emricasan: Phase II started

Conatus began an open-label, U.S. Phase II trial to evaluate 25 mg oral emricasan twice daily for 28 days in about 20 patients

Read the full 235 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE